|
Real-time Estimate
Cboe BZX
11:47:14 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 53.63 USD | +0.02% |
|
-6.59% | +79.96% |
| 08-03 | TG Therapeutics, Inc. Raises Earnings Guidance for the Full Year 2026 | CI |
| 08-03 | TG Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: TG Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,488 | 1,584 | 2,416 | 4,320 | 4,358 | 7,606 | - | - |
| Change | - | -36.33% | 52.51% | 78.8% | 0.88% | 74.52% | - | - |
| Enterprise Value (EV) 1 | 2,257 | 1,494 | 2,299 | 4,384 | 4,462 | 7,775 | 7,258 | 6,714 |
| Change | - | -33.82% | 53.89% | 90.74% | 1.76% | 74.25% | -6.65% | -7.5% |
| P/E | -7.22x | -8.1x | 190x | 201x | 10.8x | 55.1x | 19x | 14.8x |
| PBR | 11.5x | 27.3x | 15.8x | 21.7x | - | - | - | - |
| PEG | - | 0.2x | -2x | 3x | 0x | -0.8x | 0x | 0.5x |
| Capitalization / Revenue | 372x | 569x | 10.3x | 13.1x | 7.07x | 7.92x | 5.77x | 4.68x |
| EV / Revenue | 337x | 536x | 9.84x | 13.3x | 7.24x | 8.1x | 5.5x | 4.13x |
| EV / EBITDA | -6.55x | -7.76x | 110x | 104x | 36.2x | 34.5x | 14x | 11.5x |
| EV / EBIT | -6.55x | -7.75x | 111x | 105x | 36.2x | 35.9x | 13.8x | 9.73x |
| EV / FCF | -7.62x | -8.48x | -73.2x | -108x | -179x | 40.9x | 10.8x | 9.18x |
| FCF Yield | -13.1% | -11.8% | -1.37% | -0.93% | -0.56% | 2.45% | 9.22% | 10.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.63 | -1.46 | 0.09 | 0.15 | 2.77 | 0.9733 | 2.826 | 3.622 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 6.689 | 2.785 | 233.7 | 329 | 616.3 | 960.3 | 1,319 | 1,626 |
| EBITDA 1 | -344.5 | -192.5 | 20.84 | 42 | 123.4 | 225.5 | 517.5 | 585 |
| EBIT 1 | -344.8 | -192.8 | 20.63 | 41.93 | 123.3 | 216.8 | 524.3 | 689.7 |
| Net income 1 | -348.1 | -198.3 | 12.67 | 23.38 | 447.2 | 160.8 | 444.6 | 569.1 |
| Net Debt 1 | -231.1 | -90.54 | -117.4 | 64.54 | 103.7 | 169 | -348 | -892 |
| Reference price 2 | 19.00 | 11.83 | 17.08 | 30.10 | 29.81 | 53.62 | 53.62 | 53.62 |
| Nbr of stocks (in thousands) | 130,950 | 133,915 | 141,455 | 143,519 | 146,198 | 141,848 | - | - |
| Announcement Date | 3/1/22 | 2/28/23 | 2/28/24 | 3/3/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 55.09x | 8.1x | 34.48x | -.--% | 7.61B | |
| 32.69x | 11.85x | 24.08x | 0.6% | 1,025B | |
| 28.77x | 6.4x | 17.91x | 2.06% | 623B | |
| 32.89x | 7.71x | 15.93x | 2.67% | 459B | |
| 104.62x | 5.85x | 24.82x | 2.37% | 355B | |
| 18.99x | 4.63x | 11.47x | 2.87% | 336B | |
| 20.13x | 5.23x | 12.95x | 3.06% | 270B | |
| 20.27x | 4.21x | 12x | 2.1% | 247B | |
| 25.72x | 6.72x | 11.97x | 2.48% | 220B | |
| -44.61x | 6.5x | 25.4x | 2.23% | 183B | |
| Average | 29.46x | 6.72x | 19.10x | 2.04% | 372.58B | |
| Weighted average by Cap. | 31.78x | 7.65x | 18.74x | 1.94% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- TGTX Stock
- Valuation TG Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
